Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LT2011 who wrote (11399)	7/2/2012 12:45:26 PM
From: Mammon	1 Recommendation Read Replies (1) \| Respond to of 13111

no, SG needs it at 3 to be above water!

To: LT2011 who wrote (11399)	7/2/2012 1:22:21 PM
From: LurkeyTurkey	1 Recommendation Read Replies (2) \| Respond to of 13111

IMO, in order to get a respectable upward movement (that is, a jump that holds and doesn't fade away like an old soldier), PVCT needs a respectable (one that Mr. Market recognizes as such) Derm deal from a recognized Big Pharma (or similar name). An SPA, if and when PVCT gets it, has long since been anticipated and discounted and an SPA pop in the share price could easily drop back very quickly - PVCT still would need to fund the PIII trial and everyone knows that. But a really good Derm deal has NOT been discounted and could enable PVCT to shed the Rodney Dangerfield cloak of disrespect because it would be the industry's stamp of approval on PVCT's technology and, even though it would relate to PH-10 rather than PV-10, to my mind, the industry's recognition is more important to the stock price right at this time than an FDA SPA go-ahead.